Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-12

AUTHORS

Matthew David Morgan, Matthew Szeto, Michael Walsh, David Jayne, Kerstin Westman, Niels Rasmussen, Thomas F. Hiemstra, Oliver Flossmann, Annelies Berden, Peter Höglund, Lorraine Harper, on behalf of the European Vasculitis Society

ABSTRACT

BACKGROUND: Relapse of disease is frequent in anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV). It is unclear whether persistent ANCA when starting maintenance therapy increases the risk of relapse. We examined the association between ANCA status and relapse in two randomised controlled trials. METHODS: ANCA-positive patients in two trials, CYCLOPS and IMPROVE, were switched from cyclophosphamide to maintenance therapy after achieving clinical remission. We classified patients as being either ANCA-positive or ANCA-negative at the time they started maintenance therapy. We compared the risk of relapse in ANCA-positive and ANCA-negative patients. RESULTS: Of 252 patients included, 102 (40%) experienced at least one relapse during the follow-up period. At the time of the switch from induction to maintenance therapy, 111 were ANCA-positive, of whom 55 (50%) relapsed, compared to 141 patients who were ANCA-negative, of whom 47 (33%) relapsed. In multivariable time-to-event analysis, a reduced risk of relapse was associated with having become ANCA-negative at the time of switching to maintenance therapy (hazard ratio 0.63, 95% confidence interval 0.42-0.95; p = 0.026). In addition, initial proteinase 3 (PR3)-ANCA, younger age, lower serum creatinine, pulsed cyclophosphamide for remission induction, and mycophenolate mofetil for remission maintenance were all associated with an increased risk of relapse. CONCLUSIONS: Becoming ANCA-negative before the switch to maintenance is associated with a reduced risk of relapse. TRIAL REGISTRATION: CYCLOPS: ClinicalTrials.gov, NCT00430105 . Registered retrospectively on 31 January 2007. IMPROVE: ClinicalTrials.gov, NCT00307645 . Registered retrospectively on 27 March 2006. More... »

PAGES

129

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13075-017-1321-1

DOI

http://dx.doi.org/10.1186/s13075-017-1321-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1085909648

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28592297


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Antineutrophil Cytoplasmic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclophosphamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunosuppressive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Maintenance Chemotherapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Outcome Assessment (Health Care)", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proportional Hazards Models", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recurrence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Remission Induction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Queen Elizabeth Hospital Birmingham", 
          "id": "https://www.grid.ac/institutes/grid.415490.d", 
          "name": [
            "Renal Immunobiology, Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK", 
            "Queen Elizabeth Hospital Birmingham, Area 5, Level 7, Mindelsohn Way, Edgbaston, B15 2WB, Birmingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Morgan", 
        "givenName": "Matthew David", 
        "id": "sg:person.01222554244.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01222554244.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Birmingham", 
          "id": "https://www.grid.ac/institutes/grid.6572.6", 
          "name": [
            "Renal Immunobiology, Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Szeto", 
        "givenName": "Matthew", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hamilton Health Sciences", 
          "id": "https://www.grid.ac/institutes/grid.413615.4", 
          "name": [
            "Departments of Medicine and Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada", 
            "Population Health Research Institute, Hamilton Health Sciences/McMaster University, Hamilton, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Walsh", 
        "givenName": "Michael", 
        "id": "sg:person.0737266762.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0737266762.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Cambridge", 
          "id": "https://www.grid.ac/institutes/grid.5335.0", 
          "name": [
            "Department of Medicine, Addenbrooke\u2019s Hospital, University of Cambridge, Cambridge, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jayne", 
        "givenName": "David", 
        "id": "sg:person.010556472637.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010556472637.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Department of Nephrology, Skane University Hospital Malm\u00f6, Lund University, Lund, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Westman", 
        "givenName": "Kerstin", 
        "id": "sg:person.01044443465.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01044443465.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Statens Serum Institut", 
          "id": "https://www.grid.ac/institutes/grid.6203.7", 
          "name": [
            "Department of Autoimmune Serology, Statens Seruminstitut, Copenhagen, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rasmussen", 
        "givenName": "Niels", 
        "id": "sg:person.0753055037.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753055037.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Addenbrooke's Hospital", 
          "id": "https://www.grid.ac/institutes/grid.120073.7", 
          "name": [
            "School of Clinical Medicine, University of Cambridge and Cambridge Clinical Trials Unit, Addenbrooke\u2019s Hospital, Cambridge, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hiemstra", 
        "givenName": "Thomas F.", 
        "id": "sg:person.01146723406.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01146723406.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Royal Berkshire Hospital", 
          "id": "https://www.grid.ac/institutes/grid.416094.e", 
          "name": [
            "Renal Department, Royal Berkshire Hospital, Reading, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Flossmann", 
        "givenName": "Oliver", 
        "id": "sg:person.0730215065.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0730215065.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Leiden University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.10419.3d", 
          "name": [
            "Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Berden", 
        "givenName": "Annelies", 
        "id": "sg:person.0610527753.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610527753.91"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sk\u00e5ne University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411843.b", 
          "name": [
            "Competence Centre for Clinical Research, Skane University Hospital, Lund, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "H\u00f6glund", 
        "givenName": "Peter", 
        "id": "sg:person.01112556665.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01112556665.63"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Birmingham", 
          "id": "https://www.grid.ac/institutes/grid.6572.6", 
          "name": [
            "Renal Immunobiology, Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Harper", 
        "givenName": "Lorraine", 
        "id": "sg:person.01014111314.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014111314.84"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "on behalf of the European Vasculitis Society", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1093/rheumatology/keu452", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002428954"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.23800", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003700271"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2014-206404", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005210296"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.33361", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006303086"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.2010.1658", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007611727"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/ard.2010.137778", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008449896"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/rheumatology/keq244", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014636475"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1404231", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014688727"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/acr.20176", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018063959"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/acr.20176", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018063959"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/rheumatology/kei272", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019193773"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1046/j.1523-1755.2003.00769.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019606219", 
          "https://doi.org/10.1046/j.1523-1755.2003.00769.x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1523-1755.2003.00769.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019606219"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2011-200477", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026546971"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2796.2008.02060.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028952255"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/rheumatology/ker280", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029052127"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/rheumatology/ker112", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033081345"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.20234", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034919584"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/annrheumdis-2012-201750", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035281878"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/ard.2008.094714", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037321152"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.34562", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041131430"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0272-6386(03)00025-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048054246"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/art.39450", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048708276"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.autrev.2013.11.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053420270"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.autrev.2013.11.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053420270"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/biomet/78.3.691", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059420201"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/ndt/gfw211", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059933382"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3899/jrheum.110705", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071542665"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7326/0003-4819-143-9-200511010-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1073708415"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7326/0003-4819-150-10-200905190-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1073710439"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-12", 
    "datePublishedReg": "2017-12-01", 
    "description": "BACKGROUND: Relapse of disease is frequent in anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV). It is unclear whether persistent ANCA when starting maintenance therapy increases the risk of relapse. We examined the association between ANCA status and relapse in two randomised controlled trials.\nMETHODS: ANCA-positive patients in two trials, CYCLOPS and IMPROVE, were switched from cyclophosphamide to maintenance therapy after achieving clinical remission. We classified patients as being either ANCA-positive or ANCA-negative at the time they started maintenance therapy. We compared the risk of relapse in ANCA-positive and ANCA-negative patients.\nRESULTS: Of 252 patients included, 102 (40%) experienced at least one relapse during the follow-up period. At the time of the switch from induction to maintenance therapy, 111 were ANCA-positive, of whom 55 (50%) relapsed, compared to 141 patients who were ANCA-negative, of whom 47 (33%) relapsed. In multivariable time-to-event analysis, a reduced risk of relapse was associated with having become ANCA-negative at the time of switching to maintenance therapy (hazard ratio 0.63, 95% confidence interval 0.42-0.95; p\u2009=\u20090.026). In addition, initial proteinase 3 (PR3)-ANCA, younger age, lower serum creatinine, pulsed cyclophosphamide for remission induction, and mycophenolate mofetil for remission maintenance were all associated with an increased risk of relapse.\nCONCLUSIONS: Becoming ANCA-negative before the switch to maintenance is associated with a reduced risk of relapse.\nTRIAL REGISTRATION: CYCLOPS: ClinicalTrials.gov, NCT00430105 . Registered retrospectively on 31 January 2007.\nIMPROVE: ClinicalTrials.gov, NCT00307645 . Registered retrospectively on 27 March 2006.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s13075-017-1321-1", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.3725285", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1297499", 
        "issn": [
          "1478-6354", 
          "1478-6362"
        ], 
        "name": "Arthritis Research & Therapy", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "19"
      }
    ], 
    "name": "Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse", 
    "pagination": "129", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "75829cf873f04395aebf4f1246a113fdea26616a3ff2b834ebc183c95f7d043b"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28592297"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101154438"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13075-017-1321-1"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1085909648"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13075-017-1321-1", 
      "https://app.dimensions.ai/details/publication/pub.1085909648"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T10:04", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000347_0000000347/records_89826_00000003.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs13075-017-1321-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13075-017-1321-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13075-017-1321-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13075-017-1321-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13075-017-1321-1'


 

This table displays all metadata directly associated to this object as RDF triples.

333 TRIPLES      21 PREDICATES      76 URIs      40 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13075-017-1321-1 schema:about N2594bdeaf3d8425a88c21a5b81fbff9b
2 N3651ebe2d56b425bacffddf5597618c5
3 N4f8d4cc40bee47ec8c20b0884b6503e6
4 N54ec5eda1a4c48349f2b1785305c2528
5 N5c886173e70d4124a0e64a2ba9c985aa
6 N5f007e3c1efd44efab3bb630dc11dc88
7 N62e3eb97ce6a443b907c74afc5891a81
8 N63a71d5ef4094518a0aa79ca63655d66
9 N645a62b9d3ba4f899fa64a63f116208e
10 N6bd8fee923474d16aa098d9925b3e0c8
11 N75524d6ce16644b1bda7fa3629bb8d74
12 N8d2c8929ac2f474797c2c58cb5afd022
13 Na2d4ee63a7f64d4ea302c3bf2853d8af
14 Nb6865980e4fd4fcbbbec04f9a1fe3ac6
15 Nc3be6c5d08d64bc5b9cca54483737724
16 Ncf5f80fb832b427895bc47bfb2c9afe3
17 Neb749dbeb5a24bb6ad2e8752f67da03b
18 Nf033fd7de99c4596b5820dd7f2eeb91f
19 Nf18a15c921bf4fcfb9a8ade3ab61b729
20 anzsrc-for:11
21 anzsrc-for:1103
22 schema:author Nbc3a20286a83480ca42f4d94a4a8c925
23 schema:citation sg:pub.10.1046/j.1523-1755.2003.00769.x
24 https://doi.org/10.1001/jama.2010.1658
25 https://doi.org/10.1002/acr.20176
26 https://doi.org/10.1002/art.20234
27 https://doi.org/10.1002/art.23800
28 https://doi.org/10.1002/art.33361
29 https://doi.org/10.1002/art.34562
30 https://doi.org/10.1002/art.39450
31 https://doi.org/10.1016/j.autrev.2013.11.003
32 https://doi.org/10.1016/s0272-6386(03)00025-8
33 https://doi.org/10.1046/j.1523-1755.2003.00769.x
34 https://doi.org/10.1056/nejmoa1404231
35 https://doi.org/10.1093/biomet/78.3.691
36 https://doi.org/10.1093/ndt/gfw211
37 https://doi.org/10.1093/rheumatology/kei272
38 https://doi.org/10.1093/rheumatology/keq244
39 https://doi.org/10.1093/rheumatology/ker112
40 https://doi.org/10.1093/rheumatology/ker280
41 https://doi.org/10.1093/rheumatology/keu452
42 https://doi.org/10.1111/j.1365-2796.2008.02060.x
43 https://doi.org/10.1136/annrheumdis-2011-200477
44 https://doi.org/10.1136/annrheumdis-2012-201750
45 https://doi.org/10.1136/annrheumdis-2014-206404
46 https://doi.org/10.1136/ard.2008.094714
47 https://doi.org/10.1136/ard.2010.137778
48 https://doi.org/10.3899/jrheum.110705
49 https://doi.org/10.7326/0003-4819-143-9-200511010-00005
50 https://doi.org/10.7326/0003-4819-150-10-200905190-00004
51 schema:datePublished 2017-12
52 schema:datePublishedReg 2017-12-01
53 schema:description BACKGROUND: Relapse of disease is frequent in anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV). It is unclear whether persistent ANCA when starting maintenance therapy increases the risk of relapse. We examined the association between ANCA status and relapse in two randomised controlled trials. METHODS: ANCA-positive patients in two trials, CYCLOPS and IMPROVE, were switched from cyclophosphamide to maintenance therapy after achieving clinical remission. We classified patients as being either ANCA-positive or ANCA-negative at the time they started maintenance therapy. We compared the risk of relapse in ANCA-positive and ANCA-negative patients. RESULTS: Of 252 patients included, 102 (40%) experienced at least one relapse during the follow-up period. At the time of the switch from induction to maintenance therapy, 111 were ANCA-positive, of whom 55 (50%) relapsed, compared to 141 patients who were ANCA-negative, of whom 47 (33%) relapsed. In multivariable time-to-event analysis, a reduced risk of relapse was associated with having become ANCA-negative at the time of switching to maintenance therapy (hazard ratio 0.63, 95% confidence interval 0.42-0.95; p = 0.026). In addition, initial proteinase 3 (PR3)-ANCA, younger age, lower serum creatinine, pulsed cyclophosphamide for remission induction, and mycophenolate mofetil for remission maintenance were all associated with an increased risk of relapse. CONCLUSIONS: Becoming ANCA-negative before the switch to maintenance is associated with a reduced risk of relapse. TRIAL REGISTRATION: CYCLOPS: ClinicalTrials.gov, NCT00430105 . Registered retrospectively on 31 January 2007. IMPROVE: ClinicalTrials.gov, NCT00307645 . Registered retrospectively on 27 March 2006.
54 schema:genre research_article
55 schema:inLanguage en
56 schema:isAccessibleForFree true
57 schema:isPartOf N682d456b44574a03b9090998e17eba86
58 N85d536be91c844499997af4590ab7c56
59 sg:journal.1297499
60 schema:name Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse
61 schema:pagination 129
62 schema:productId N80ff9f41bf5f4f328bc8c631f3382a15
63 Nc7c77ead1dab43248a891789af2389ae
64 Nd1bdb30a16454aaa831beec96af202fe
65 Ndc012d60e0814ea1965e02759f04622f
66 Nf15de4355e6e4b06b14c0bb317f2c698
67 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085909648
68 https://doi.org/10.1186/s13075-017-1321-1
69 schema:sdDatePublished 2019-04-11T10:04
70 schema:sdLicense https://scigraph.springernature.com/explorer/license/
71 schema:sdPublisher N36e12737c62746d9b297225dec9bbbc8
72 schema:url https://link.springer.com/10.1186%2Fs13075-017-1321-1
73 sgo:license sg:explorer/license/
74 sgo:sdDataset articles
75 rdf:type schema:ScholarlyArticle
76 N06ed581b77e94ee8ad3559143e85740b rdf:first sg:person.01112556665.63
77 rdf:rest N6c9263ac55884741befce020a22d3ea5
78 N11c53e8ec30a4eb6bc77db3b9caea047 rdf:first Nea572f81b5224fa69942cb11dd0ae147
79 rdf:rest Nfc3496d6b0a14d53acba21af235e5a47
80 N24010ec94e80432dacee8729139aefa5 rdf:first sg:person.0730215065.29
81 rdf:rest N78f8a60c5fcf4b02b1103872d867230c
82 N2594bdeaf3d8425a88c21a5b81fbff9b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
84 rdf:type schema:DefinedTerm
85 N2f5281a04f43476b858fb81fd0b07357 rdf:first N873bc2b358d54ddb9378efb3ca6d0911
86 rdf:rest rdf:nil
87 N3651ebe2d56b425bacffddf5597618c5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Remission Induction
89 rdf:type schema:DefinedTerm
90 N36e12737c62746d9b297225dec9bbbc8 schema:name Springer Nature - SN SciGraph project
91 rdf:type schema:Organization
92 N3ffd57bb207249afba0af9bcbc746d1c schema:name Department of Nephrology, Skane University Hospital Malmö, Lund University, Lund, Sweden
93 rdf:type schema:Organization
94 N4f8d4cc40bee47ec8c20b0884b6503e6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Proportional Hazards Models
96 rdf:type schema:DefinedTerm
97 N54ec5eda1a4c48349f2b1785305c2528 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Male
99 rdf:type schema:DefinedTerm
100 N5c886173e70d4124a0e64a2ba9c985aa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Outcome Assessment (Health Care)
102 rdf:type schema:DefinedTerm
103 N5f007e3c1efd44efab3bb630dc11dc88 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Risk Factors
105 rdf:type schema:DefinedTerm
106 N62e3eb97ce6a443b907c74afc5891a81 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Recurrence
108 rdf:type schema:DefinedTerm
109 N63a71d5ef4094518a0aa79ca63655d66 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Middle Aged
111 rdf:type schema:DefinedTerm
112 N645a62b9d3ba4f899fa64a63f116208e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Antibodies, Antineutrophil Cytoplasmic
114 rdf:type schema:DefinedTerm
115 N682d456b44574a03b9090998e17eba86 schema:issueNumber 1
116 rdf:type schema:PublicationIssue
117 N6bd8fee923474d16aa098d9925b3e0c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Female
119 rdf:type schema:DefinedTerm
120 N6c9263ac55884741befce020a22d3ea5 rdf:first sg:person.01014111314.84
121 rdf:rest N2f5281a04f43476b858fb81fd0b07357
122 N75524d6ce16644b1bda7fa3629bb8d74 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Aged
124 rdf:type schema:DefinedTerm
125 N7664ee94e5a8469c9778b130b5838eed rdf:first sg:person.0753055037.32
126 rdf:rest Ne1e24547e4c24765b236b789803fb520
127 N78f8a60c5fcf4b02b1103872d867230c rdf:first sg:person.0610527753.91
128 rdf:rest N06ed581b77e94ee8ad3559143e85740b
129 N80ff9f41bf5f4f328bc8c631f3382a15 schema:name dimensions_id
130 schema:value pub.1085909648
131 rdf:type schema:PropertyValue
132 N85d536be91c844499997af4590ab7c56 schema:volumeNumber 19
133 rdf:type schema:PublicationVolume
134 N873bc2b358d54ddb9378efb3ca6d0911 schema:familyName on behalf of the European Vasculitis Society
135 rdf:type schema:Person
136 N8d2c8929ac2f474797c2c58cb5afd022 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Maintenance Chemotherapy
138 rdf:type schema:DefinedTerm
139 Na2d4ee63a7f64d4ea302c3bf2853d8af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Retrospective Studies
141 rdf:type schema:DefinedTerm
142 Nb6865980e4fd4fcbbbec04f9a1fe3ac6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Humans
144 rdf:type schema:DefinedTerm
145 Nbc3a20286a83480ca42f4d94a4a8c925 rdf:first sg:person.01222554244.03
146 rdf:rest N11c53e8ec30a4eb6bc77db3b9caea047
147 Nc3be6c5d08d64bc5b9cca54483737724 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Immunosuppressive Agents
149 rdf:type schema:DefinedTerm
150 Nc7c77ead1dab43248a891789af2389ae schema:name pubmed_id
151 schema:value 28592297
152 rdf:type schema:PropertyValue
153 Ncf5f80fb832b427895bc47bfb2c9afe3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Randomized Controlled Trials as Topic
155 rdf:type schema:DefinedTerm
156 Nd1bdb30a16454aaa831beec96af202fe schema:name nlm_unique_id
157 schema:value 101154438
158 rdf:type schema:PropertyValue
159 Nd1f329c0e42f4d8bb520c2e6cb6b613d rdf:first sg:person.010556472637.30
160 rdf:rest Ne966b7830fa04c88b3ae239cf0fd2b30
161 Ndc012d60e0814ea1965e02759f04622f schema:name readcube_id
162 schema:value 75829cf873f04395aebf4f1246a113fdea26616a3ff2b834ebc183c95f7d043b
163 rdf:type schema:PropertyValue
164 Ne1e24547e4c24765b236b789803fb520 rdf:first sg:person.01146723406.09
165 rdf:rest N24010ec94e80432dacee8729139aefa5
166 Ne966b7830fa04c88b3ae239cf0fd2b30 rdf:first sg:person.01044443465.02
167 rdf:rest N7664ee94e5a8469c9778b130b5838eed
168 Nea572f81b5224fa69942cb11dd0ae147 schema:affiliation https://www.grid.ac/institutes/grid.6572.6
169 schema:familyName Szeto
170 schema:givenName Matthew
171 rdf:type schema:Person
172 Neb749dbeb5a24bb6ad2e8752f67da03b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Adult
174 rdf:type schema:DefinedTerm
175 Nf033fd7de99c4596b5820dd7f2eeb91f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Cyclophosphamide
177 rdf:type schema:DefinedTerm
178 Nf15de4355e6e4b06b14c0bb317f2c698 schema:name doi
179 schema:value 10.1186/s13075-017-1321-1
180 rdf:type schema:PropertyValue
181 Nf18a15c921bf4fcfb9a8ade3ab61b729 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Disease-Free Survival
183 rdf:type schema:DefinedTerm
184 Nfc3496d6b0a14d53acba21af235e5a47 rdf:first sg:person.0737266762.50
185 rdf:rest Nd1f329c0e42f4d8bb520c2e6cb6b613d
186 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
187 schema:name Medical and Health Sciences
188 rdf:type schema:DefinedTerm
189 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
190 schema:name Clinical Sciences
191 rdf:type schema:DefinedTerm
192 sg:grant.3725285 http://pending.schema.org/fundedItem sg:pub.10.1186/s13075-017-1321-1
193 rdf:type schema:MonetaryGrant
194 sg:journal.1297499 schema:issn 1478-6354
195 1478-6362
196 schema:name Arthritis Research & Therapy
197 rdf:type schema:Periodical
198 sg:person.01014111314.84 schema:affiliation https://www.grid.ac/institutes/grid.6572.6
199 schema:familyName Harper
200 schema:givenName Lorraine
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014111314.84
202 rdf:type schema:Person
203 sg:person.01044443465.02 schema:affiliation N3ffd57bb207249afba0af9bcbc746d1c
204 schema:familyName Westman
205 schema:givenName Kerstin
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01044443465.02
207 rdf:type schema:Person
208 sg:person.010556472637.30 schema:affiliation https://www.grid.ac/institutes/grid.5335.0
209 schema:familyName Jayne
210 schema:givenName David
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010556472637.30
212 rdf:type schema:Person
213 sg:person.01112556665.63 schema:affiliation https://www.grid.ac/institutes/grid.411843.b
214 schema:familyName Höglund
215 schema:givenName Peter
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01112556665.63
217 rdf:type schema:Person
218 sg:person.01146723406.09 schema:affiliation https://www.grid.ac/institutes/grid.120073.7
219 schema:familyName Hiemstra
220 schema:givenName Thomas F.
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01146723406.09
222 rdf:type schema:Person
223 sg:person.01222554244.03 schema:affiliation https://www.grid.ac/institutes/grid.415490.d
224 schema:familyName Morgan
225 schema:givenName Matthew David
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01222554244.03
227 rdf:type schema:Person
228 sg:person.0610527753.91 schema:affiliation https://www.grid.ac/institutes/grid.10419.3d
229 schema:familyName Berden
230 schema:givenName Annelies
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0610527753.91
232 rdf:type schema:Person
233 sg:person.0730215065.29 schema:affiliation https://www.grid.ac/institutes/grid.416094.e
234 schema:familyName Flossmann
235 schema:givenName Oliver
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0730215065.29
237 rdf:type schema:Person
238 sg:person.0737266762.50 schema:affiliation https://www.grid.ac/institutes/grid.413615.4
239 schema:familyName Walsh
240 schema:givenName Michael
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0737266762.50
242 rdf:type schema:Person
243 sg:person.0753055037.32 schema:affiliation https://www.grid.ac/institutes/grid.6203.7
244 schema:familyName Rasmussen
245 schema:givenName Niels
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753055037.32
247 rdf:type schema:Person
248 sg:pub.10.1046/j.1523-1755.2003.00769.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1019606219
249 https://doi.org/10.1046/j.1523-1755.2003.00769.x
250 rdf:type schema:CreativeWork
251 https://doi.org/10.1001/jama.2010.1658 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007611727
252 rdf:type schema:CreativeWork
253 https://doi.org/10.1002/acr.20176 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018063959
254 rdf:type schema:CreativeWork
255 https://doi.org/10.1002/art.20234 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034919584
256 rdf:type schema:CreativeWork
257 https://doi.org/10.1002/art.23800 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003700271
258 rdf:type schema:CreativeWork
259 https://doi.org/10.1002/art.33361 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006303086
260 rdf:type schema:CreativeWork
261 https://doi.org/10.1002/art.34562 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041131430
262 rdf:type schema:CreativeWork
263 https://doi.org/10.1002/art.39450 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048708276
264 rdf:type schema:CreativeWork
265 https://doi.org/10.1016/j.autrev.2013.11.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053420270
266 rdf:type schema:CreativeWork
267 https://doi.org/10.1016/s0272-6386(03)00025-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048054246
268 rdf:type schema:CreativeWork
269 https://doi.org/10.1046/j.1523-1755.2003.00769.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1019606219
270 rdf:type schema:CreativeWork
271 https://doi.org/10.1056/nejmoa1404231 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014688727
272 rdf:type schema:CreativeWork
273 https://doi.org/10.1093/biomet/78.3.691 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059420201
274 rdf:type schema:CreativeWork
275 https://doi.org/10.1093/ndt/gfw211 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059933382
276 rdf:type schema:CreativeWork
277 https://doi.org/10.1093/rheumatology/kei272 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019193773
278 rdf:type schema:CreativeWork
279 https://doi.org/10.1093/rheumatology/keq244 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014636475
280 rdf:type schema:CreativeWork
281 https://doi.org/10.1093/rheumatology/ker112 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033081345
282 rdf:type schema:CreativeWork
283 https://doi.org/10.1093/rheumatology/ker280 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029052127
284 rdf:type schema:CreativeWork
285 https://doi.org/10.1093/rheumatology/keu452 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002428954
286 rdf:type schema:CreativeWork
287 https://doi.org/10.1111/j.1365-2796.2008.02060.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1028952255
288 rdf:type schema:CreativeWork
289 https://doi.org/10.1136/annrheumdis-2011-200477 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026546971
290 rdf:type schema:CreativeWork
291 https://doi.org/10.1136/annrheumdis-2012-201750 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035281878
292 rdf:type schema:CreativeWork
293 https://doi.org/10.1136/annrheumdis-2014-206404 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005210296
294 rdf:type schema:CreativeWork
295 https://doi.org/10.1136/ard.2008.094714 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037321152
296 rdf:type schema:CreativeWork
297 https://doi.org/10.1136/ard.2010.137778 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008449896
298 rdf:type schema:CreativeWork
299 https://doi.org/10.3899/jrheum.110705 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071542665
300 rdf:type schema:CreativeWork
301 https://doi.org/10.7326/0003-4819-143-9-200511010-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073708415
302 rdf:type schema:CreativeWork
303 https://doi.org/10.7326/0003-4819-150-10-200905190-00004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073710439
304 rdf:type schema:CreativeWork
305 https://www.grid.ac/institutes/grid.10419.3d schema:alternateName Leiden University Medical Center
306 schema:name Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands
307 rdf:type schema:Organization
308 https://www.grid.ac/institutes/grid.120073.7 schema:alternateName Addenbrooke's Hospital
309 schema:name School of Clinical Medicine, University of Cambridge and Cambridge Clinical Trials Unit, Addenbrooke’s Hospital, Cambridge, UK
310 rdf:type schema:Organization
311 https://www.grid.ac/institutes/grid.411843.b schema:alternateName Skåne University Hospital
312 schema:name Competence Centre for Clinical Research, Skane University Hospital, Lund, Sweden
313 rdf:type schema:Organization
314 https://www.grid.ac/institutes/grid.413615.4 schema:alternateName Hamilton Health Sciences
315 schema:name Departments of Medicine and Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Canada
316 Population Health Research Institute, Hamilton Health Sciences/McMaster University, Hamilton, Canada
317 rdf:type schema:Organization
318 https://www.grid.ac/institutes/grid.415490.d schema:alternateName Queen Elizabeth Hospital Birmingham
319 schema:name Queen Elizabeth Hospital Birmingham, Area 5, Level 7, Mindelsohn Way, Edgbaston, B15 2WB, Birmingham, UK
320 Renal Immunobiology, Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
321 rdf:type schema:Organization
322 https://www.grid.ac/institutes/grid.416094.e schema:alternateName Royal Berkshire Hospital
323 schema:name Renal Department, Royal Berkshire Hospital, Reading, UK
324 rdf:type schema:Organization
325 https://www.grid.ac/institutes/grid.5335.0 schema:alternateName University of Cambridge
326 schema:name Department of Medicine, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
327 rdf:type schema:Organization
328 https://www.grid.ac/institutes/grid.6203.7 schema:alternateName Statens Serum Institut
329 schema:name Department of Autoimmune Serology, Statens Seruminstitut, Copenhagen, Denmark
330 rdf:type schema:Organization
331 https://www.grid.ac/institutes/grid.6572.6 schema:alternateName University of Birmingham
332 schema:name Renal Immunobiology, Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
333 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...